A global survey of physicians' perceptions on cholesterol management: The from the heart study

International Journal of Clinical Practice

Volumn 61, Issue 7, 2007, Pages 1078-1085

  Erhardt, L R ^a   Hobbs, F D R ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DEATH; DRUG DOSE TITRATION; DYSLIPIDEMIA; FEMALE; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MALE; NORMAL HUMAN; PERCEPTION; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK FACTOR; SMOKING;

ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; GUIDELINE ADHERENCE; HEALTH SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIFE STYLE; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE; QUESTIONNAIRES; RISK FACTORS;

EID: 34250685879     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01420.x     Document Type: Review

References (32)

1. World Health Organisation. The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva: World Health Organisation 2002.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 285: 2486 97.
3. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 110: 227 39.
4. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003 10: S1 10.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 360: 7 22.
6. Colhoun HM, Betteridge DJ, Durrington PN et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 364: 685 96.
7. Sever PS, Dahlof B, Poulter NR, Wedel H et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004 64 (Suppl. 2 43 60.
8. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 333: 1301 7.
9. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 279: 1615 22.
10. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators (CARE). N Engl J Med 1996 335: 1001 9.
11. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998 339: 1349 57.
12. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 350: 1495 504.
13. Koren MJ, Hunninghake DB, ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 2004 44: 1772 9.
14. LaRosa JC, Grundy SM, Waters DD et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352: 1425 35.
15. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005 294: 2437 45.
16. Amarenco P, Bogousslavsky J, Callahan A III. et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 355: 549 59.
17. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000 160: 459 67.
18. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001 22: 554 72.
19. Schwandt P, Brady AJ. Achieving lipid goals in Europe: how large is the treatment gap? Expert Rev Cardiovasc Ther 2004 2: 431 49.
20. Van Ganse E, Laforest L, Alemao E et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005 21: 1389 99.
21. Davidson MH, Maki C, Pearson TA et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II Survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005 96: 556 63.
22. Gaw A. A new reality: achieving cholesterol-lowering goals in clinical practice. Atheroscler Suppl 2002 2: 5 8.
23. Foley KA, Simpson RJ Jr., Crouse JR III. et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003 92: 79 81.
24. Frolkis JP, Pearce GL, Nambi V et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002 113: 625 9.
25. Neal RC, Jones PH. Lipid-lowering: can ezetimibe help close the treatment gap? Cleve Clin J Med 2003 70: 777 83.
26. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002 19: 596 604.
27. Heidrich J, Behrens T, Raspe F, Keil U. Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany. Eur J Cardiovasc Prev Rehabil 2005 12: 521 9.
28. Christian AH, Mills T, Simpson SL, Mosca L. Quality of cardiovascular disease preventive care and physician/practice characteristics. J Gen Intern Med 2006 21: 231 7.
29. Ito MK, Delucca GM, Aldridge MA. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Ther 2001 6: 129 35.
30. Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002 18: 220 8.
31. Bourgault C, Davignon J, Fodor G et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study-Observational (CALIPSO). Can J Cardiol 2005 21: 1187 93.
32. Brady AJB, Norrie J, Ford I. Statin prescribing: is the reality meeting the expectations of primary care? Br J Cardiol 2005 12: 397 400.